BBIO - Apellis Pharmaceuticals sees takeover interest from large pharma - Bloomberg

2023-04-02 16:32:28 ET

• Apellis Pharmaceuticals ( NASDAQ: APLS ) has attracted takeover interest from large pharmaceutical companies.
• The biotech firm that's focused on rare diseases and opthalmology is talking to advisers to consider its options, according to a Bloomberg report , which cited people familiar. Apellis ( APLS ) may also looks at partnerships or licensing agreements for some of its opthalmology  products.
• There's no certainty a transaction will occur and Apellis prefers to remain independent, according to the report.
• In November Apellis ( APLS ) announced that the U.S. Food and Drug Administration (FDA) accepted the company's additional data filed for an application seeking approval of intravitreal pegcetacoplan to treat geographic atrophy ( GA ) secondary to age-related macular degeneration ( AMD ).
• The Apellis ( APLS ) report comes after Bloomberg report late last month that BridgeBio Pharma ( BBIO ) is garnering takeover interest from big pharma companies.

For further details see: